Our results provide substantial evidence for the hypothesis that Cdk inhibitor P276-00 enhances doxorubicin-induced killing of NSCLC cells in vitro as well as in vivo without any significant toxicity especially in p53 positive tumors. Here, TP53 is linked to non-small cell lung carcinoma.